GB201417456D0 - Treatment of cancer - Google Patents

Treatment of cancer

Info

Publication number
GB201417456D0
GB201417456D0 GBGB1417456.9A GB201417456A GB201417456D0 GB 201417456 D0 GB201417456 D0 GB 201417456D0 GB 201417456 A GB201417456 A GB 201417456A GB 201417456 D0 GB201417456 D0 GB 201417456D0
Authority
GB
United Kingdom
Prior art keywords
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1417456.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karo Pharma AB
Original Assignee
Karo Bio AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karo Bio AB filed Critical Karo Bio AB
Priority to GBGB1417456.9A priority Critical patent/GB201417456D0/en
Publication of GB201417456D0 publication Critical patent/GB201417456D0/en
Priority to PCT/EP2015/072763 priority patent/WO2016050945A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1417456.9A 2014-10-02 2014-10-02 Treatment of cancer Ceased GB201417456D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1417456.9A GB201417456D0 (en) 2014-10-02 2014-10-02 Treatment of cancer
PCT/EP2015/072763 WO2016050945A1 (en) 2014-10-02 2015-10-01 Pharmaceutical combinations comprising estrogen receptor-beta agonists with platinum drugs or paclitaxel for treating ovarian cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417456.9A GB201417456D0 (en) 2014-10-02 2014-10-02 Treatment of cancer

Publications (1)

Publication Number Publication Date
GB201417456D0 true GB201417456D0 (en) 2014-11-19

Family

ID=51946756

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1417456.9A Ceased GB201417456D0 (en) 2014-10-02 2014-10-02 Treatment of cancer

Country Status (2)

Country Link
GB (1) GB201417456D0 (en)
WO (1) WO2016050945A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114249680B (en) * 2022-01-10 2022-12-27 深圳市乐土生物医药有限公司 Indole derivatives, and synthesis method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377918B2 (en) * 2005-01-31 2013-02-19 ACC Therapeutics Inc Apigenin for chemoprevention, and chemotherapy combined with therapeutic reagents
US8367665B2 (en) * 2008-04-16 2013-02-05 Karo Bio Ab Estrogen receptor ligands

Also Published As

Publication number Publication date
WO2016050945A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
IL250677B (en) Treatment of cancers using anti-nkg2a agents
FI3851537T3 (en) Treatment of hyperbilirubinemia
RS61536B1 (en) Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
IL285077A (en) Compounds for treatment of cancer
SG11201607130RA (en) Combination method for treatment of cancer
PT3622953T (en) Combination treatment of cancer
HK1231561A1 (en) Cancer treatment
IL263835A (en) Exosome-guided treatment of cancer
GB201416832D0 (en) Methods of treatment
GB201409363D0 (en) Skin cancer treatment
GB201408297D0 (en) Treatment of cancer
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201417456D0 (en) Treatment of cancer
GB201407837D0 (en) Methods of cancer therapy
GB201622214D0 (en) treatment of cancer
GB201604621D0 (en) Treatment of cancer
GB201512723D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer
GB201417465D0 (en) Treatment of cancers
PT3851537T (en) Treatment of hyperbilirubinemia

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)